Screener
Rhythm Pharmaceuticals, Inc. RYTM Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredRevenueCurrent.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Accounts payable | $12,299 | $13,947 |
| Accrued expenses and other current liabilities | 80,045 | 83,855 |
| Lease liability | 676 | 650 |
| Deferred revenue | 48 | 194 |
| Deferred royalty obligation, current | 10,130 | 7,296 |
| Total current liabilities | 103,198 | 105,942 |
| Long-term liabilities: | ||
| Deferred royalty obligation | 98,339 | 100,886 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s deferred revenue?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported deferred revenue of $48K in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s deferred revenue changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s deferred revenue decreased by 96.3% year-over-year, from $1.3M to $48K.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s deferred revenue?
- Over 4 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s deferred revenue has grown at a -59.2% compound annual growth rate (CAGR), from $7M to $194K.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude